News

The NDA is based on global clinical trial results from the large, multi-center, randomized, double-blind, placebo-controlled, outcomes Phase III Systolic Heart failure treatment with the If inhibitor ivabradine

The new facility is designed to help biopharmaceutical companies develop manufacturing processes and find solutions to processing challenges in collaboration with engineers from EMD. EMD Millipore president and

This is its fourth dedicated research centre in South Africa and brings Synexus global site count to 24 with 3 new centres being opened in the last six

The ‘829 patent application includes newly allowed claims directed to compositions comprising a double-stranded molecule of between 19 and 52 nucleotides in each strand with various end configurations,

Using Ayasdi’s patented topological learning technology, Ayasdi Care can examine millions of patient cases across a provider’s own facilities to rapidly ascertain pathways that deliver the highest quality

The vaccine is intended to stimulate the immune system to fight the cancer cells while a PD-1 pathway inhibitor is designed to prevent the cancer cells from camouflaging

In this study, ZA-305, Androxal exhibited superiority in several assessments, particularly the two co-primary endpoints: percent change from baseline in average sperm concentration and percent of subjects considered

Both the companies will be responsible for jointly developing products which will be commercialized by Amerigen in the US. As part of the deal, Menovo will oversee manufacturing

Limitx is a new, early stage technology apart from the company’s other abuse deterrent technologies Aversion and Impede. The NIDA grant is based on a proposal submitted by